Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eugene Schiff

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

Gastroenterology

Hepatology

Gastroenterology

2016

English

HBV Serum DNA and RNA Levels in Nucleos(t)ide Analogue-Treated or Untreated Patients During Chronic and Acute Infection

English

Related publications

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

English

Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus

English

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

The Lancet

Medicine

2010

English

High Efficacy of Sofosbuvir/Velpatasvir and Impact of Baseline Resistance-Associated Substitutions in Hepatitis C Genotype 3 Infection

Alimentary Pharmacology and Therapeutics

English

Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia

American Journal of Hematology

Hematology

2018

English

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy

English

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Digestive Diseases and Sciences

Physiology

Gastroenterology

2016

English

Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof-Of-Concept, Single-Centre, Open-Label Phase 2a Cohort Study

The Lancet Infectious Diseases

Infectious Diseases

2015

English

NS5A-P32 Deletion After Failure of Ledipasvir/Sofosbuvir in Hepatitis C Virus Genotype 1b Infection

English

Amanote Research

Discover open access scientific publications

Search, annotate, share and cite publications

Publications by Eugene Schiff

Efficacy of Sofosbuvir, Velpatasvir, and GS-9857 in Patients With Genotype 1 Hepatitis C Virus Infection in an Open-Label, Phase 2 Trial

HBV Serum DNA and RNA Levels in Nucleos(t)ide Analogue-Treated or Untreated Patients During Chronic and Acute Infection

Related publications

Efficacy of the Combination of Sofosbuvir, Velpatasvir, and the NS3/4A Protease Inhibitor GS-9857 in Treatment-Naïve or Previously Treated Patients With Hepatitis C Virus Genotype 1 or 3 Infections

Sofosbuvir-Velpatasvir-Voxilaprevir With or Without Ribavirin in Direct-Acting Antiviral-Experienced Patients With Genotype 1 Hepatitis C Virus

Efficacy of Boceprevir, an NS3 Protease Inhibitor, in Combination With Peginterferon Alfa-2b and Ribavirin in Treatment-Naive Patients With Genotype 1 Hepatitis C Infection (SPRINT-1): An Open-Label, Randomised, Multicentre Phase 2 Trial

High Efficacy of Sofosbuvir/Velpatasvir and Impact of Baseline Resistance-Associated Substitutions in Hepatitis C Genotype 3 Infection

Sofosbuvir/Velpatasvir for Chronic Hepatitis C Infection in Patients With Transfusion-Dependent Thalassemia

Efficacy of Glecaprevir and Pibrentasvir in Patients With Genotype 1 Hepatitis C Virus Infection With Treatment Failure After NS5A Inhibitor Plus Sofosbuvir Therapy

Efficacy and Safety of Ribavirin With Sofosbuvir Plus Ledipasvir in Patients With Genotype 1 Hepatitis C: A Meta-Analysis

Ledipasvir and Sofosbuvir for Hepatitis C Genotype 4: A Proof-Of-Concept, Single-Centre, Open-Label Phase 2a Cohort Study

NS5A-P32 Deletion After Failure of Ledipasvir/Sofosbuvir in Hepatitis C Virus Genotype 1b Infection